It depends on why Wegovy is prescribed. Medicaid can refuse semaglutide written for weight loss and still be required to pay for the same pen written for heart protection. That split comes from one line of federal law and one CMS statement, and both are short. Employer and individual plans follow different rules, set out in is Wegovy covered by insurance.
The line in the statute
A state may exclude or restrict a covered outpatient drug when the prescribed use is not a medically accepted indication[1]. It may also exclude a list of drug classes and uses, and the first is “agents when used for anorexia, weight loss, or weight gain”[1].
The statute defines a medically accepted indication as any use approved under the Food, Drug, and Cosmetic Act, or one supported by the listed drug compendia[1]. So every use printed on the label starts inside the coverage rule, and only the weight-loss use can be carved back out.
Wegovy has three labeled uses, and they land differently
The injection is approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight[3]. It is approved for weight reduction and long-term maintenance, and for a form of fatty liver disease with fibrosis under accelerated approval[3]. The tablets carry the first two uses but not the liver one[3].
| Labeled use | Form | Federal rule for a state program |
|---|---|---|
| Lower the risk of heart attack, stroke or cardiovascular death in adults with established heart disease and obesity or overweight | Injection and tablets | Must be covered as a medically accepted indication; CMS named this use in 2024 |
| Liver disease (noncirrhotic MASH with moderate to advanced fibrosis) in adults | Injection only | An FDA-approved use, so inside the general rule CMS described; not named in its example |
| Weight reduction and long-term maintenance | Injection and tablets | A state may exclude it; covering it is a state choice |
What CMS told the states
On a May 2024 call with state Medicaid programs, CMS’s Division of Pharmacy explained how a drug with one excluded use and other covered uses is handled. States must cover it for any FDA-approved indication except the one that is excluded[2].
CMS used Wegovy as the example. When it was approved for chronic weight management only, a state did not have to cover it[2]. Once the FDA added the cardiovascular indication, CMS said states “must cover Wegovy for those cardiovascular events, but still do not have to cover it for the weight loss”[2]. CMS added that a state can choose to cover weight-loss drugs through its state plan[2].
The rule change that was proposed and then dropped
In November 2024, CMS proposed reading the weight-loss exclusion more narrowly. Obesity drugs used to reduce excess weight and maintain it in people with obesity would then have counted as covered outpatient drugs that Medicaid could not exclude[4].
That did not happen. The final rule, published April 15, 2025, lists “Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program” among the proposals CMS did not intend to finalize[5]. So the state option for weight-loss use stands. The Medicare side of the same question is in does Medicare cover Wegovy.
BALANCE: the 2026 route to weight coverage
CMS’s BALANCE model negotiates GLP-1 prices and coverage terms with drug makers for state Medicaid programs that choose to join[6]. States can join from May 2026 through January 1, 2027, and every formulation of Wegovy is on the drug list, for weight management as well as its existing uses[6].
Participation is voluntary for states and makers[6]. CMS says patients face qualifications set in the negotiations, including prior authorization, and that the model will not guarantee coverage for any individual[6]. Your state Medicaid agency or managed care plan can tell you whether it has joined.
How many states covered it before BALANCE
One study read state Medicaid formularies and preferred drug lists from the first quarter of 2023, and Wegovy was among the antiobesity medications it assessed[7]. Of 47 states with public preferred drug lists, 10 covered at least one antiobesity medication and 5 did so without restriction[7].
The authors note the lists may have changed since early 2023[7]. CMS still called the cardiovascular indication recent in May 2024[2], so a count from early 2023 measured weight coverage, not heart coverage. For the diabetes brand of the same molecule, see does Medicaid cover Ozempic, and for one large state’s own list, does Medi-Cal cover Ozempic.
If Medicaid says no
The Wegovy savings card is for commercial insurance, where it can bring a month to as little as $25[8]. Anyone enrolled in a government program, including Medicaid, counts as government-insured for the offer, even with commercial coverage alongside[8].
Government-insured patients can still pay the maker’s self-pay price outside their insurance[8]. For the pen that is $199 a month for the first 2 fills at the starting doses for new patients, then $349 through 2.4 mg[8]. The tablets start at $149 a month at 1.5 mg[8]. Those payments do not count toward a deductible or out-of-pocket limit[8].
What each dose costs in full is in Wegovy cost, and the card’s commercial terms are in Wegovy savings card. Compounded semaglutide is sold for cash outside Medicaid; its monthly prices are on the semaglutide price board. The question to put to your Medicaid plan first: which diagnosis does it need on the Wegovy request?